http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2872775-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e9d87c9166ae011cd0953ef2d737df |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1c1e9a2e20d4c15dade02c0a54dc39e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9791ec0130ae7c9106f27fe18ebba5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b51db5cb1f30df40123d3030d285a01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f2f7cb1b82eb0785d4192e0b9d41384 |
| publicationDate | 2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2872775-T3 |
| titleOfInvention | Pyrropyrimidine compounds as MNK inhibitors |
| abstract | Compound of formula (I), or a pharmaceutically acceptable salt thereof, **(See formula)** in which: R1 is selected from: - H, - CO-NR8R9, in which R8 and R9 are selected, each independently, from H, alkyl, cycloalkyl, and monocyclic or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted with one or more R12 groups, and said heterocycloalkyl is optionally substituted with one or more groups selected from R10 and R12 , or R8 and R9 are joined, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted with one or more groups selected from R10 and (CH2)mR12, R2 is selected from H and alkyl, wherein said alkyl group is optionally substituted with one or more R12 groups, R3 is selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may optionally be substituted with one or more The groups selected from halo, OH and alkoxy, Z1, Z2, Z3 and Z4 are all C, R4, R5, R6 and R7 are each independently selected from H, alkyl, CN, NO2, OH, alkoxy, NHCO-alkyl, halo, and haloalkyl, or Z1, Z3, and Z4 are all C, Z2 is N, R5 is absent, and R4, R6, and R7 are as defined above, or Z2, Z3, and Z4 are all C, Z1 is N, R4 is absent and R5, R6 and R7 are as defined above, each R10 and R11 is independently alkyl, each R12 is independently selected from CO2R10, COOH, OH, alkoxy, haloalkyl, NH2 , NHR10, NR10R11, heteroaryl and heterocycloalkyl, wherein said heterocycloalkyl is optionally further substituted with one or more R10 groups, R13 is H or halo, and wherein "alkyl" denotes a C1-C12 alkyl group. |
| priorityDate | 2015-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 435.